.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The recently unveiled Haryana pharma policy 2026 has received strong support from the Association of Indian Medical Device Industry (AiMeD). Consequently, stakeholders are calling it one of India's most progressive frameworks. This landmark policy aims to attract investments of over ₹10,000 crore. Furthermore, it expects to generate 20,000 jobs and foster rapid healthcare manufacturing innovation.
To accelerate growth, the state offers massive financial incentives to manufacturers. For instance, eligible units can receive a capital expenditure (CAPEX) subsidy of up to 30%, capped at ₹200 crore. Additionally, the policy provides operational expenditure (OPEX) support of up to 80%, capped at ₹20 crore annually. Therefore, these subsidies will significantly lower the initial entry barrier for domestic businesses.
Moreover, the framework addresses the critical gap in active pharmaceutical ingredients (APIs). However, India still imports many high-end medical devices despite supplying 20% of global generic medicines. Therefore, this policy directly aims to promote indigenous research and development (R&D).
In addition to financial backing, the state guarantees a transparent single-window system to ease business operations. Nevertheless, industry leaders emphasize that reducing the actual regulatory burden remains vital. Specifically, Rajiv Nath, Forum Coordinator of AiMeD, urged governments to provide a three-year compliance holiday for greenfield projects. Consequently, this grace period would let new manufacturing units align with standard safety laws smoothly.
Furthermore, the policy encourages eco-friendly practices by offering support for green manufacturing. Ultimately, these integrated efforts will establish Haryana as a preferred global destination for healthcare manufacturing.
Q1: What is the main objective of the Haryana pharma policy 2026?
The primary objective is to attract over ₹10,000 crore in investments, generate 20,000 jobs, and establish Haryana as a leading hub for indigenous pharmaceutical and medical device manufacturing.
Q2: What CAPEX and OPEX supports are offered under this policy?
The policy offers up to 30% CAPEX support (capped at ₹200 crore) and up to 80% OPEX support (capped at ₹20 crore per year for up to 10 years) to eligible manufacturing units.
Q3: Why is a compliance holiday being requested by industry bodies?
Industry leaders have requested a three-year compliance holiday for greenfield investments to eliminate arbitrary requirements, reduce the initial regulatory burden, and ensure rapid project execution.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The Association of Indian Medical Device Industry (AiMeD) has praised the Haryana Pharmaceutical and Medical Devices Manufacturing Policy 2026. The policy targets ₹10,000 crore in investments and 20,000 jobs. It offers substantial CAPEX and OPEX subsidies to boost indigenous manufacturing and reduce imports.
last month
A parliamentary panel has urged the FSSAI to finalise front-of-pack nutrition labelling regulations without further delay. The committee stressed that simple, color-coded indicators for sugar and clear warning labels are vital to combat dietary non-communicable diseases and guide informed consumer choices.
3 days back
A comprehensive analysis of the NFHS-5 data regarding postpartum anemia in India, exploring the prevalence, severity, and the socioeconomic and regional factors contributing to this public health challenge for clinicians seeking to improve maternal health outcomes.
Last week
A study in Greece reveals that 46-80% of heatwave deaths are linked to climate change. This analysis explores the implications for public health and clinical practice, particularly for elderly and vulnerable populations facing rising global temperatures in regions like India.
2 weeks back
Nearly 80% of Indians suffer from inadequate Vitamin D, causing silent bone weakening and sudden fractures. This expert guide reviews why mega-dose therapy is critical for high-risk patients, the key factors driving widespread deficiency, and the mandatory medical evaluations needed to protect skeletal health.
last month
A parliamentary standing committee has directed FSSAI to expedite front-of-pack nutrition labelling regulations. The panel highlighted that over two years of delay since the 2022 draft notification leaves consumers relying on complex numerical labels, urging simple color-coded sugar indicators and warnings.
3 days back
